CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
CG Oncology Inc. (NASDAQ:CGON) on Monday announced positive topline results from its Phase 3 PIVOT-006 trial, which Arthur Kuan, chairman, president, and CEO of CG Oncology, called a defining milestone for the company. Kuan stated that the data position cretostimogene grenadenorepvec as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase 3 study…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.